Fructosamine-3-Kinase as a Potential Treatment Option for Age-Related Macular Degeneration
Authors:
- Sander De BruyneSBSander De Bruyne
- Caroline Van Den BroeckeCBCaroline Van Den Broecke
- Henk VrielinckHVHenk Vrielinck
- Samira KhelifiSamira Khelifi
- Olivier De WeverOWOlivier De Wever
- Ken BrackeKBKen Bracke
- Manon HuizingMHManon Huizing
- Nezahat BostonNBNezahat Boston
- Jonas HimpeJHJonas Himpe
- Marijn SpeeckaertMarijn Speeckaert
- Anne VralAVAnne Vral
- Jo Van DorpeJDJo Van Dorpe
Open Access
- 4 September 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (9) , 2869
Abstract
Age-related macular degeneration is the leading cause of blindness in the developed world. Since advanced glycation end products (AGEs) are implicated in the pathogenesis of AMD through various lines of evidence, we investigated the potential of fructosamine-3-kinase (FN3K) in the disruption of retinal AGEs, drusenoid material and drusenoid lesions in patients with AMD. AGE-type autofluorescence was measured to evaluate the effects of FN3K on glycolaldehyde-induced AGE-modified neural porcine retinas and unmodified human neural retinas. Eye pairs from cigarette-smoke- and air-exposed mice were treated and evaluated histologically. Automated optical image analysis of human tissue sections was performed to compare control- and FN3K-treated drusen and near-infrared (NIR) microspectroscopy was performed to examine biochemical differences. Optical coherence tomography (OCT) was used to evaluate the effect of FN3K on drusenoid deposits after treatment of post-mortem human eyes. FN3K treatment provoked a significant decrease (41%) of AGE-related autofluorescence in the AGE-modified porcine retinas. Furthermore, treatment of human neural retinas resulted in significant decreases of autofluorescence (−24%). FN3K-treated murine eyes showed less drusenoid material. Pairwise comparison of drusen on tissue sections revealed significant changes in color intensity after FN3K treatment. NIR microspectroscopy uncovered clear spectral differences in drusenoid material (Bruch’s membrane) and drusen after FN3K treatment. Ex vivo treatment strongly reduced size of subretinal drusenoid lesions on OCT imaging (up to 83%). In conclusion, our study demonstrated for the first time a potential role of FN3K in the disruption of AGE-related retinal autofluorescence, drusenoid material and drusenoid lesions in patients with AMD.Keywords
Funding Information
- IOF grant (F2018/IOF-Advanced/411)
- Research Foundation Flanders – Hercules Foundation (AUGE/13/13 : FT-IMAGER)
This publication has 45 references indexed in Scilit:
- A Novel Source of Methylglyoxal and Glyoxal in Retina: Implications for Age-Related Macular DegenerationPLOS ONE, 2012
- Lipofuscin and N-Retinylidene-N-Retinylethanolamine (A2E) Accumulate in Retinal Pigment Epithelium in Absence of Light ExposureJournal of Biological Chemistry, 2012
- Therapeutic targets in age-related macular diseaseJournal of Clinical Investigation, 2010
- The role of advanced glycation end products in retinal ageing and diseaseBiochimica et Biophysica Acta (BBA) - General Subjects, 2009
- Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastorisBMC Biotechnology, 2009
- Mathematical model of flow in the vitreous humor induced by saccadic eye rotations: effect of geometryBiomechanics and Modeling in Mechanobiology, 2009
- Advanced Glycation End Product (AGE) Accumulation on Bruch’s Membrane: Links to Age-Related RPE DysfunctionInvestigative Ophthalmology & Visual Science, 2009
- The expression of advanced glycation endproduct receptors in rpe cells associated with basal deposits in human maculasExperimental Eye Research, 2006
- Infrared spectroscopic imaging for histopathologic recognitionNature Biotechnology, 2005
- Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytesBiochemical Journal, 2002